Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis.

Alexandra SavinkinaA David PaltielJoseph S RossGregg Gonsalves

Published in: Open forum infectious diseases (2022)

Priority for nirmatrelvir/ritonavir treatment should be given to unvaccinated persons at high risk of severe disease from COVID-19. Further priority may be assigned by weighing treatment effectiveness, disease severity, drug cost, and willingness to pay for deaths averted.

Keyphrases

coronavirus disease
randomized controlled trial
primary care
sars cov
systematic review
antiretroviral therapy
health insurance
adverse drug
replacement therapy
respiratory syndrome coronavirus
data analysis